Shares of Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report) were down 8% during trading on Tuesday . The stock traded as low as $7.41 and last traded at $7.41. Approximately 2,050 shares changed hands during mid-day trading, an increase of 42% from the average daily volume of 1,447 shares. The stock had previously closed at $8.05.
Nxera Pharma Price Performance
The business has a 50-day simple moving average of $8.10 and a two-hundred day simple moving average of $9.06.
About Nxera Pharma
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.
Further Reading
- Five stocks we like better than Nxera Pharma
- 3 Warren Buffett Stocks to Buy Now
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Which Wall Street Analysts are the Most Accurate?
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Buy P&G Now, Before It Sets A New All-Time High
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
